GNPX
Genprex Inc
$
0.214
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.226
Open
0.220
VWAP
0.21
Vol
812.96K
Mkt Cap
7.16M
Low
0.209
Amount
174.67K
EV/EBITDA(TTM)
--
Total Shares
2.10M
EV
3.94M
EV/OCF(TTM)
--
P/S(TTM)
--
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q4
FY2025Q1
FY2025Q2
--
--
-0.390
-98.23%
--
--
-0.410
-88.89%
--
--
-0.420
-86%
Estimates Revision
The market is revising No Change the revenue expectations for Genprex, Inc. (GNPX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -25.06%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-25.06%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Genprex Inc (GNPX.O) is -0.18, compared to its 5-year average forward P/E of -3.89. For a more detailed relative valuation and DCF analysis to assess Genprex Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.89
Current PE
-0.18
Overvalued PE
1.47
Undervalued PE
-9.24
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1.13
Current PS
0.00
Overvalued PS
4.53
Undervalued PS
-2.28
Financials
Annual
Quarterly
FY2025Q1
N/A
Total Revenue
FY2025Q1
YoY :
-33.81%
-3.97M
Operating Profit
FY2025Q1
YoY :
-33.58%
-3.96M
Net Income after Tax
FY2025Q1
YoY :
-92.95%
-0.26
EPS - Diluted
FY2025Q1
YoY :
-21.70%
-4.16M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
GNPX News & Events
Events Timeline
2025-06-24 (ET)
2025-06-24
09:27:04
Genprex presents positive preclinical research from studies of GPX-002
2025-06-23 (ET)
2025-06-23
09:07:39
Genprex present preclinical data, research from studies of GPX-002
2025-05-28 (ET)
2025-05-28
07:07:35
Genprex collaborators present positive preclinical data of GPX-002 in diabetes
Sign Up For More Events
Sign Up For More Events
News
7.0
08-04NewsfilterGenprex Issues Stockholder Letter and Provides 2025 Corporate Update
9.0
06-24NewsfilterGenprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
9.0
06-23NewsfilterGenprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
Sign Up For More News
People Also Watch
WHLR
Wheeler Real Estate Investment Trust Inc
2.780
USD
-1.07%
INBS
Intelligent Bio Solutions Inc
1.520
USD
-1.94%
GBR
New Concept Energy Inc
0.820
USD
-7.87%
SSY
SunLink Health Systems Inc
1.020
USD
-5.56%
DSS
DSS Inc
0.860
USD
+2.26%
CERO
CERo Therapeutics Holdings Inc
7.955
USD
-1.79%
CHNR
China Natural Resources Inc
3.310
USD
-2.36%
DDC
DDC Enterprise Ltd
12.070
USD
-2.27%
FAQ
What is Genprex Inc (GNPX) stock price today?
The current price of GNPX is 0.2138 USD — it has decreased -3.61 % in the last trading day.
What is Genprex Inc (GNPX)'s business?
What is the price predicton of GNPX Stock?
What is Genprex Inc (GNPX)'s revenue for the last quarter?
What is Genprex Inc (GNPX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Genprex Inc (GNPX)'s fundamentals?
How many employees does Genprex Inc (GNPX). have?